Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function
Status:
Unknown status
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
AIM 1 will test the hypothesis that elevation of high-density lipoprotein (HDL) through
treatment with Niaspan will accelerate the regression of atherosclerotic plaque in patients
with established atherosclerosis. The investigators will therefore study patients with
atherosclerosis in the aorta and carotid artery. Plaque quantification will be with magnetic
resonance imaging (MRI).
AIM 2 will assess the ability of Niaspan to improve endothelial function in patients with
coronary artery disease and type II diabetes mellitus, who typically have low high-density
lipoprotein cholesterol (HDL-C), and high risk of cardiovascular events.